A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
This study has been completed.
Study NCT00055471
Information provided by AstraZeneca
First Received: March 3, 2003
Last Updated: October 20, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
